Exploring the thymic origin of group 2 innate lymphoid cells

探索第 2 组先天淋巴细胞的胸腺起源

基本信息

  • 批准号:
    10472249
  • 负责人:
  • 金额:
    $ 61.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-15 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Abstract Innate lymphoid cells (ILCs) play diverse roles in shaping innate and adaptive immunity. These cells exist as heterogeneous populations and their identities are influenced by their tissue environments. Likewise, the ontogeny of ILCs is also complex. Although ILCs are thought to arise from bone marrow progenitors or tissue resident progenitors distributed during embryogenesis, work from our laboratory strongly suggest that ILCs at least ILC2s can also be generated in the thymus, not only from multipotent progenitors but also from committed T cell precursors. Our recent data using single cell RNA sequencing suggest that a substantial fraction of the ILC-enriched population in the blood of wild type mice (WT) come from the thymus, and their equivalents can also be found in peripheral tissues. We thus hypothesize that the thymus exports a substantial amount of ILC precursors to the circulation, which may replenish ILC2s and/or other ILCs in peripheral tissues in steady-state or upon immune challenges and the thymus-derived ILCs may have distinct functions. In this renewal proposal, we intend to follow up on these new exciting findings and determine the function of these thymus-derived ILC precursors and their biological significant. We will further characterize thymus-derived ILC-precursors in the lung and small intestine and determine their frequencies during mouse development. We will also identify thymus-derived ILC precursors in human blood, thus gaining appreciation of the clinical relevance of these cells. We will then focus on learning the function of these thymus-derived ILC precursors using in vitro and in vivo approaches, as well as adoptive transfer of purified ILC precursors into Rag2-/-Il2g-/- mice which are devoid of ILCs. The behaviors of these cells in type 2 immune reactions will be monitored. Finally, we will assess the cell-intrinsic functional differences among WT ILC2s generated from bone marrow common lymphoid progenitors (CLP) and thymic DN1 and DN3 T cell precursors. Taken together, studies outlined in this proposal will further our understanding of thymus-derived ILCs, which will help establish a new paradigm regarding to the production and maintenance of ILC pools. Because the presence of an active thymus represents one of the major differences between children and adults, knowledge about thymus-derived ILCs may shed light on their different immune responses such as those during Covid-19 infection.
摘要 先天淋巴样细胞(ILCs)在形成先天免疫和获得性免疫中发挥着不同的作用。这些单元格以 异质种群及其身份受其组织环境的影响。同样, ILC的个体发育也是复杂的。尽管ILC被认为起源于骨髓祖细胞或组织 在胚胎发育过程中分布的常驻祖细胞,我们实验室的工作强烈表明ILCs在 最少的ILC2也可以在胸腺中产生,不仅来自多能祖细胞,也来自 承诺的T细胞前体。我们最近使用单细胞RNA测序的数据表明,大量的 野生型小鼠(WT)血液中ILC富集群的一部分来自胸腺,他们的 在外周组织中也可以找到等价物。因此,我们假设胸腺输出一种 大量ILC前体进入循环,可补充ILC2和/或其他ILC 在处于稳定状态或免疫挑战的外周组织中,胸腺来源的ILCs可能 有不同的功能。在这项更新建议中,我们打算跟进这些令人振奋的新发现,并 确定这些胸腺来源的ILC前体的功能及其生物学意义。我们将进一步 肺和小肠中胸腺来源的ILC前体的特征及其频率的测定 在老鼠发育过程中。我们还将在人类血液中鉴定胸腺来源的ILC前体,从而获得 对这些细胞的临床相关性的评价。然后我们将重点学习这些组件的功能 使用体外和体内方法的胸腺来源的ILC前体以及过继转移纯化的 ILC前体转化为缺失ILC的Rag2-/-IL2G-/-小鼠。这些细胞在2型免疫中的行为 人们的反应将受到监控。最后,我们将评估WT ILC2之间的细胞固有功能差异 从骨髓共同淋巴祖细胞(CLP)和胸腺DN1和DN3 T细胞前体产生。 综上所述,这项建议中概述的研究将进一步加深我们对胸腺来源的ILCs的理解,它 将有助于建立关于生产和维护ILC池的新范例。因为 活跃胸腺的存在代表了儿童和成人的主要区别之一,即知识 关于胸腺来源的ILC可能有助于揭示它们的不同免疫反应,例如新冠肺炎期间的免疫反应 感染。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Correlation between circulating innate lymphoid cell precursors and thymic function.
  • DOI:
    10.1016/j.isci.2022.103732
  • 发表时间:
    2022-02-18
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Bajana S;Pankow A;Liu K;Michniowska M;Urban JF Jr;Chen WR;Sun XH
  • 通讯作者:
    Sun XH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiao-Hong Sun其他文献

Xiao-Hong Sun的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiao-Hong Sun', 18)}}的其他基金

Establishing a lineage tracing system for studying thymus-derived innate lymphoid cells
建立研究胸腺源性先天淋巴细胞谱系追踪系统
  • 批准号:
    10644626
  • 财政年份:
    2023
  • 资助金额:
    $ 61.8万
  • 项目类别:
γδTCR-dependent and independent differentiation of innate lymphoid cells
先天淋巴细胞的γδTCR依赖性和独立分化
  • 批准号:
    10749563
  • 财政年份:
    2023
  • 资助金额:
    $ 61.8万
  • 项目类别:
Exploring the thymic origin of group 2 innate lymphoid cells
探索第 2 组先天淋巴细胞的胸腺起源
  • 批准号:
    9295975
  • 财政年份:
    2016
  • 资助金额:
    $ 61.8万
  • 项目类别:
Asb2 in CD4+ T cell lineage differentiation and its plasticity
Asb2在CD4 T细胞谱系分化及其可塑性中的作用
  • 批准号:
    8660033
  • 财政年份:
    2013
  • 资助金额:
    $ 61.8万
  • 项目类别:
Asb2 in CD4+ T cell lineage differentiation and its plasticity
Asb2在CD4 T细胞谱系分化及其可塑性中的作用
  • 批准号:
    8452778
  • 财政年份:
    2013
  • 资助金额:
    $ 61.8万
  • 项目类别:
Notch-induced protein degradation in lymphopoiesis
Notch 诱导淋巴细胞生成中的蛋白质降解
  • 批准号:
    8099313
  • 财政年份:
    2010
  • 资助金额:
    $ 61.8万
  • 项目类别:
COBRE:OMRF: BHLH PROTEINS IN HUMAN LYMPHOPOIESIS
COBRE:OMRF:人类淋巴细胞生成中的 BHLH 蛋白
  • 批准号:
    7170300
  • 财政年份:
    2005
  • 资助金额:
    $ 61.8万
  • 项目类别:
COBRE:OMRF: BHLH PROTEINS IN HUMAN LYMPHOPOIESIS
COBRE:OMRF:人类淋巴细胞生成中的 BHLH 蛋白
  • 批准号:
    7011737
  • 财政年份:
    2004
  • 资助金额:
    $ 61.8万
  • 项目类别:
E2A turnover and Notch-controlled lymphocyte development
E2A转换和Notch控制的淋巴细胞发育
  • 批准号:
    6675261
  • 财政年份:
    2003
  • 资助金额:
    $ 61.8万
  • 项目类别:
E2A turnover and Notch-controlled lymphocyte development
E2A转换和Notch控制的淋巴细胞发育
  • 批准号:
    6843129
  • 财政年份:
    2003
  • 资助金额:
    $ 61.8万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 61.8万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 61.8万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 61.8万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 61.8万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 61.8万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 61.8万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 61.8万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 61.8万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 61.8万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 61.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了